Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis
- 5 May 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Neurology and Neurosurgery
- Vol. 195, 105886
- https://doi.org/10.1016/j.clineuro.2020.105886
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Fingolimod Immune Effects Beyond Its Sequestration AbilityNeurology and Therapy, 2019
- Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literatureExperimental and Therapeutic Medicine, 2018
- Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the LiteratureCase Reports in Neurology, 2018
- Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosisClinical Immunology, 2017
- The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseasesClinical Immunology, 2017
- Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor AgonistsScience, 2002